Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 DiabetesAuthor of the article:THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountSAN FRANCISCO & NEW YORK & MONTREAL — Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today announced a partnership with Breakthrough T1D, the leading global Type 1 Diabetes (T1D) research and advocacy organization, and an award through its Industry Discovery and Development Partnership (IDDP) program to support the advancement of Encellin’s ENCRT-103-hPI clinical program in T1D.The new trial (NCT07680673) will bring ENCRT-103-hPI, Encellin’s immune-protected implant configuration, into the clinic. ENCRT-103-hPI builds on the successful completion of NCT06408311, Encellin’s first-in-human Phase 1 study, which demonstrated non-fibrotic tissue integration, vascularization, and viable human islets within retrieved ENC-201 implants. NCT07680673 is designed to test whether this next-generation implant can safely support and protect transplanted islets in people with T1D, and will be conducted in Canada. The planned study will assess safety, tolerability, and local tissue response, including vascular integration around the implant, the ENCRT membrane’s ability to exclude immune cells, and survival of the donor islets.For people living with T1D, replacing the insulin-producing cells lost to the disease has the potential to address the underlying disease rather than continually managing its consequences. Today, however, islet transplantation requires systemic immunosuppression to protect transplanted cells. Encellin is developing ENCRT with the long-term goal of enabling cell replacement therapies that can survive and function while being protected from the immune system, without the need for immunosuppression.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“People with Type 1 Diabetes manage their disease every hour of every day. Our vision is a future where replacing the cells lost to T1D and protecting them instead of suppressing the patient’s immune response can become a practical therapeutic option for many more people,” said Crystal Nyitray, PhD, founder and CEO of Encellin. “This study represents an important step toward that goal. We are grateful to Breakthrough T1D for sharing that vision and for supporting the careful clinical work required to determine whether an immune-protected cell replacement approach can ultimately deliver meaningful benefit to people living with T1D.”“Islet Cell replacement has enormous potential to transform the lives of people with Type 1 Diabetes, but protecting transplanted insulin-producing cells from the immune system without the need for immune suppressive drugs remains one of the field’s central challenges,” said Asja Guzman, Associate Director at Breakthrough T1D. “Breakthrough T1D is committed to advancing approaches to help overcome this barrier. Encellin’s clinical program provides an opportunity to validate a retrievable, immune-protective device can safely support the long-term function of transplanted islets in people with T1D, and we are pleased to collaborate in this next stage of development.”About the Encellin–Breakthrough T1D CollaborationBreakthrough T1D’s Industry Discovery and Development Partnership program supports promising industry programs with the potential to accelerate the development of therapies for the treatment, prevention and cure of T1D. Under the 24-month, $2.5 million award, Breakthrough T1D will support advancement of Encellin’s ENCRT-103-hPI clinical program, including the planned Phase 1 study in adults with T1D.Encellin, Inc. is a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), a retrievable thin-film platform designed to enable therapeutic cells to survive and function in the body. Encellin’s lead clinical programs are focused on advancing cell replacement approaches for people living with Type 1 Diabetes.For more information, visit www.encellin.com.About Breakthrough T1D, Formerly JDRFAs the leading global Type 1 Diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with Type 1 Diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.Forward-Looking StatementsThis press release contains forward-looking statements regarding the potential benefit of the ENCRT platform, including its ability to address fibrosis, immune protection, viability of human cells, and potential applications in Type 1 Diabetes and other endocrine or metabolic diseases, development plans and vision for future programs or potential therapeutic applications. The ENCRT platform’s development for use with allogeneic islets in patients with Type 1 Diabetes is being evaluated in clinical studies, and its safety and effectiveness for this use has not been established. These statements are based on current expectations and are subject to risks and uncertainties including risks associated with early-stage clinical development, the possibility of unfavorable preclinical or clinical results, regulatory review and approval process, manufacturing challenges, and the ability to advance programs as planned. Actual results may differ materially from those expressed or implied. Encellin undertakes no obligation to update forward-looking statements contained in this press release as a result of new information or future events.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.